Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2024

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

10. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:


	June 30,		December 31,
($ in thousands)	2024		2023

Accounts payable	$	37,957	$	34,810
Accrued expenses:
Professional fees		2,260		1,681
Salaries, bonus and related benefits		4,903		8,531
Research and development		8,547		11,644
Accrued royalties payable		1,656		2,015
Accrued coupon and rebates		6,596		9,987
Return reserve		3,214		4,077
Other¹		3,788		817
Total accounts payable and accrued expenses	$	68,921	$	73,562

Note 1: Includes approximately $1.4 million of accrued consideration related to Mustang’s Asset Purchase Agreement with uBriGene (see Note 3) as of June 30, 2024.